An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&kgrB activation, BAFF-dependent NF-&kgrB activation, and does not alter NF-&kgrB activation without BAFF and APRIL is useful as a therapeutic agent.
